[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. Valued at a market cap of $386.3 billion, the company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta to treat blood cancers, among others. 

Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks." ABBV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and...

Fundamentals

See More
  • Market Capitalization, $K 386,273,952
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,332 M
  • EBITDA $ 24,318 M
  • 60-Month Beta 0.32
  • Price/Sales 6.22
  • Price/Cash Flow 14.22
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 27.24% (+0.02%)
  • Historical Volatility 22.89%
  • IV Percentile 51%
  • IV Rank 52.16%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 7) 5.17 (2.38%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 4,937
  • Volume Avg (30-Day) 15,752
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 248,457
  • Open Int (30-Day) 253,892
  • Expected Range 212.04 to 222.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.77
  • Number of Estimates 9
  • High Estimate $3.93
  • Low Estimate $3.66
  • Prior Year $2.97
  • Growth Rate Est. (year over year) +26.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
200.02 +8.58%
on 05/08/26
220.01 -1.29%
on 05/22/26
+13.29 (+6.52%)
since 04/29/26
3-Month
190.75 +13.86%
on 04/29/26
237.11 -8.41%
on 03/04/26
-14.90 (-6.42%)
since 02/27/26
52-Week
181.73 +19.51%
on 06/27/25
244.81 -11.29%
on 10/01/25
+34.09 (+18.62%)
since 05/28/25

Most Recent Stories

More News
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 149.22 (-1.10%)
JNJ : 226.23 (-1.98%)
ABBV : 216.09 (-1.16%)
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill. , May 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO ® (venetoclax) to include...

ABBV : 216.09 (-1.16%)
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

HIMS : 25.94 (+2.21%)
NVO : 45.55 (+0.09%)
LLY : 1,093.46 (-2.96%)
ABBV : 216.09 (-1.16%)
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ...

ABBV : 216.09 (-1.16%)
5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold.

MDLZ : 61.65 (-1.19%)
NVDA : 216.27 (+0.94%)
GOOGL : 383.54 (-1.69%)
AAPL : 311.38 (-0.36%)
KO : 79.26 (-1.43%)
CVX : 181.76 (-0.69%)
COP : 113.72 (-1.10%)
SCHD : 32.52 (-0.34%)
ABBV : 216.09 (-1.16%)
TXN : 309.54 (-2.03%)
UNH : 376.90 (-1.47%)
MSFT : 442.71 (+3.68%)
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

NORTH CHICAGO, Ill. , May 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive...

ABBV : 216.09 (-1.16%)
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

 - Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant...

ABBV : 216.09 (-1.16%)
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

NORTH CHICAGO, Ill. , May 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced that the European Medicines Agency's...

ABBV : 216.09 (-1.16%)
2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical

ABBV : 216.09 (-1.16%)
AbbVie Stock: Is Wall Street Bullish or Bearish?

AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.

$SPX : 7,587.85 (+0.32%)
PPH : 104.48 (-1.16%)
ABBV : 216.09 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 223.51
2nd Resistance Point 221.44
1st Resistance Point 220.04
Last Price 216.09
1st Support Level 216.56
2nd Support Level 214.49
3rd Support Level 213.09

See More

52-Week High 244.81
Fibonacci 61.8% 220.71
Last Price 216.09
Fibonacci 50% 213.27
Fibonacci 38.2% 205.83
52-Week Low 181.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.